GlassScriptPhysician profile
Shazia Nasir
NPI 1538256953
$9,019.48
in general payments reported to CMS, 2019-2025
47 companies · $1,213 in 2025
The $1,213 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,485 · 2020: $990 · 2021: $1,146 · 2022: $1,321 · 2023: $1,499 · 2024: $1,366 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,077.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,527.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $965.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $858.79 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $680.01 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $623.55 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $503.50 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $353.11 | 2019-2022 | |
| Pfizer INC. | $331.26 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $303.57 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $254.51 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $238.51 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.17 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $201.42 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $193.59 | 2022-2025 | Freestyle Libre 3 |
| Organogenesis INC. | $168.33 | 2023 | Puraply |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shazia Nasir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.